Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

By A. L. Bon, G. Schiavoni, G. D'agostino, I. Gresser, F. Belardelli, D. Tough. Immunity, 2001

1,048 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/e85f39870205ccf885d112b5c868718ae4830a93

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Shizuo Akira
2. Jacques Banchereau
3. T. Mogensen
4. B. Beutler
5. K. Takeda
6. Taro Kawai
7. T. Kaisho
8. R. Steinman

Citations in the corpus

• In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination (2004, methodology): “The greater sensitivity for class I presentation may not be due to inherent differences in priming OVA-specific CD8 T cells relative to CD4 T cells, because when we injected preprocessed MHC class I and II binding peptides with CFA, the latter were more effective immunogens (Fig.”
• Shared and Distinct Functions of Type I and Type III Interferons (2019, neutral): “…cell activation and cytotoxicity (e.g., NKp46 and class I MHC), and (5) inducing dendritic cells (DCs) to produce chemokines (e.g., CXCL9 and CXCL10) and cytokines (e.g., IL-15) that enhance cross-presentation and promote T cell proliferation and survival (Crouse et al., 2015; Le Bon et al., 2003).”
• Regulation of T cell immunity by dendritic cells. (2001, background): “In addition pDCs produce large amounts of IFN I, another Th1 polar- ing DCs in vivo (Le Bon et al., 2001).”
• Toll-like receptors. (2003, background): “Type I IFNs induce production of antigen-specific immunoglobulins with all isotypes in a dendritic cell–dependent manner (273).”
• Inferences, questions and possibilities in Toll-like receptor signalling (2004, background): “Interferon-β has a particularly important part to pla”
• Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. (2003, methodology): “1 106 deobserved adjuvant effect of type I IFN on humoral im- pleted or nondepleted PBMCs were then cultured with or without 104 influenza virus particles (Charles Rivers) in a 48-well plate withmune responses (Le Bon et al., 2001).”
• Type I interferon is selectively required by dendritic cells for immune rejection of tumors (2011, neutral): “B cell differentiation, antibody production, and isotype class switching were also enhanced by type I IFN’s effects either di­ rectly on B cells or indirectly via effects on T cells (Coro et al., 2006; Le Bon et al., 2006b) and DCs (Le Bon et al., 2001).”
• HMGB1 is an endogenous immune adjuvant released by necrotic cells (2004, background): “RAGE activation results in nuclear factor-kB (NF-kB) translocation (Andersson et al, 2002), and the NF-kB pathway is responsible for most events elicited by necrotic cells (Li et al, 2001).”